Race Oncology Ltd has released a press release.
Preclinical & Clinical Programs Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Zantrene highly effective in Melanoma preclinical study
- First Patient Dosed in Phase 1b/2 AML Trial
- Race executes Israel AML Phase 2 Trial Contract
- Race Executes Key Contract for Israel Phase 2 AML Trial
- Contract to Commence Phase 2 Extramedullary AML Trial
Later from Racura Oncology
- Race secures fifth US patent for Zantrene
- Race secures sixth US patent for Zantrene
- University of Wollongong R&D Collaboration
- Breakthrough Zantrene Heart Protection Discovery
- AGM Presentations
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology